User:NickCT/LixiLan

LixiLan is the trade name of a drug being developed by Sanofi for treatment of diabetes. The drug is a combination therapy and combines the two diabetes drugs insulin glargine and lixisenatide. In 2016 Sanofi announced the drug had produced positive results in Phase III clinical trails and suggested that the drug would be approved by the Food and Drug Administration in 2017.